These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1417 related items for PubMed ID: 8282068

  • 1. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
    Lindsay RM, Altar CA, Cedarbaum JM, Hyman C, Wiegand SJ.
    Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
    [Abstract] [Full Text] [Related]

  • 2. A preclinical development strategy designed to optimize the use of glial cell line-derived neurotrophic factor in the treatment of Parkinson's disease.
    Lapchak PA.
    Mov Disord; 1998 Nov; 13 Suppl 1():49-54. PubMed ID: 9613719
    [Abstract] [Full Text] [Related]

  • 3. Neuronal transplantation and neurotrophic factors in the treatment of Parkinson's disease--update February 1995.
    Kupsch A, Oertel WH, Earl CD, Sautter J.
    J Neural Transm Suppl; 1995 Nov; 46():193-207. PubMed ID: 8821056
    [Abstract] [Full Text] [Related]

  • 4. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L, Garris BL, Garris DR, Lau YS.
    Neuroscience; 2006 Jun 19; 140(1):67-76. PubMed ID: 16533572
    [Abstract] [Full Text] [Related]

  • 5. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ, Kaplitt MG, Stern MB, Eidelberg D.
    Hum Gene Ther; 2001 Aug 10; 12(12):1589-91. PubMed ID: 11529246
    [Abstract] [Full Text] [Related]

  • 6. Neurotrophic factors and Parkinson's disease: the emergence of a new player?
    Dauer W.
    Sci STKE; 2007 Nov 06; 2007(411):pe60. PubMed ID: 17986711
    [Abstract] [Full Text] [Related]

  • 7. Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons.
    Porritt MJ, Batchelor PE, Howells DW.
    Exp Neurol; 2005 Mar 06; 192(1):226-34. PubMed ID: 15698637
    [Abstract] [Full Text] [Related]

  • 8. In vivo gene delivery of glial cell line--derived neurotrophic factor for Parkinson's disease.
    Kordower JH.
    Ann Neurol; 2003 Mar 06; 53 Suppl 3():S120-32; discussion S132-4. PubMed ID: 12666104
    [Abstract] [Full Text] [Related]

  • 9. Neurotrophic factors for the treatment of Parkinson's disease.
    Sullivan AM, Toulouse A.
    Cytokine Growth Factor Rev; 2011 Jun 06; 22(3):157-65. PubMed ID: 21689963
    [Abstract] [Full Text] [Related]

  • 10. Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease.
    Watanabe Y, Himeda T, Araki T.
    Med Sci Monit; 2005 Jan 06; 11(1):RA17-23. PubMed ID: 15614202
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease.
    Anglade P, Vyas S, Javoy-Agid F, Herrero MT, Michel PP, Marquez J, Mouatt-Prigent A, Ruberg M, Hirsch EC, Agid Y.
    Histol Histopathol; 1997 Jan 06; 12(1):25-31. PubMed ID: 9046040
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections.
    Kozlowski DA, Connor B, Tillerson JL, Schallert T, Bohn MC.
    Exp Neurol; 2000 Nov 06; 166(1):1-15. PubMed ID: 11031079
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Parkinson's disease: contemporary state and perspectives.
    Mokrý J.
    Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove; 1994 Nov 06; 37(1):5-12. PubMed ID: 7761792
    [Abstract] [Full Text] [Related]

  • 17. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M, Iwatsubo T, Mizuno Y, Mochizuki H.
    J Neurochem; 2004 Oct 06; 91(2):451-61. PubMed ID: 15447678
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Neurotrophic factors for the treatment of Parkinson's disease.
    Chiocco MJ, Harvey BK, Wang Y, Hoffer BJ.
    Parkinsonism Relat Disord; 2007 Oct 06; 13 Suppl 3():S321-8. PubMed ID: 18267258
    [Abstract] [Full Text] [Related]

  • 20. [Recent progress in development of psychotropic drugs (3)--Antiparkinsonian agents applied in the treatment of Parkinson's disease or are under investigation for patients or model animals].
    Nomoto M.
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1996 Aug 06; 16(4):113-22. PubMed ID: 8905800
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 71.